Drug Treatment Services

Alison Thewliss Excerpts

Tuesday 16th July 2019 Westminster Hall

[Alison Thewliss (Glasgow Central) (SNP)]

I am glad that the hon. Member for Manchester, Withington (Jeff Smith) secured this debate, because it is very timely for Glasgow and for Scotland more widely.

Let me start by saying that every single one of the 1,187 deaths last year is a tragedy—a tragedy for the families who lost a loved one and, as the hon. Member for Glasgow North East (Mr Sweeney) said, a tragedy because of the potential that was lost as a result of that person passing away. We should bear those people in mind whenever we talk about drugs policy.

Ideally, I want those people, who have an illness, to be able to get medical help as if they had any other illness. If they had cancer, we would not stigmatise the cancer drug that kept them well. That is what methadone does—it supports people and stabilises their lives.

[Luke Graham]

rose—

[Alison Thewliss]

I will not hear a word from the hon. Gentleman against that.

[Luke Graham]

It is not stigmatisation; it is data led. We saw information today that more people die from the use of methadone. I am not asking the hon. Lady to cancel anything; I am asking whether she will join me in calling for a review. We need a review of all our drug laws across the board. She knows that I agree with her on many aspects of this policy. I seek a review, not to cancel out or stigmatise.

[Alison Thewliss]

When the hon. Gentleman talks about methadone, the result is that he stigmatises it. That may not be his intention, but that is the result. He may have heard Kirsten Horsburgh from the Scottish Drugs Forum talking on “Good Morning Scotland” this morning about that being stigmatising for people. We need to get away from that stigma. We need to look towards treatment and harm reduction.

To that end, I and my SNP colleagues have argued for three years for a drug consumption room for Glasgow. That could go ahead as a pilot if the UK Government got out of the way and let us do it. It is three years since NHS Greater Glasgow and Clyde produced its “Taking away the chaos” report, the business case for that drug consumption room, which Saket Priyadarshi and his colleagues worked away on. That has been sitting there for three years. The UK Government are standing in the way of the life-saving intervention a drug consumption room would bring.

That drug consumption room would not save everybody—at the moment, it would be just for Glasgow—but it would make a huge difference to the people I know who inject in dirty bin sheds and back lanes and on waste ground yards from my office, time and again. It is the job of the rest of society to try to pick up the pieces of that—to pick up the discarded needles that are left behind. Those people would have the dignity of a drug consumption room within a few paces, where they could go to inject drugs, receive medical help and get support now, if the UK Government approved it. It is an absolute tragedy that that is not happening, and a huge source of frustration.

The hon. Member for Glasgow North East (Mr Sweeney) mentioned the Lord Advocate. The Lord Advocate is the Lord Advocate; we cannot intervene in the decisions that the chief legal officer takes on this. If he says that that is not within the law, that is his legal opinion. He is the chief legal officer, and that is his decision. It rests with the UK Government to make that change under the Misuse of Drugs Act 1971.

[Luke Graham]

Will the hon. Lady give way?

[Alison Thewliss]

I have already given way to the hon. Gentleman, and I am short of time.

The Misuse of Drugs Act is reserved. Where we have had powers in Scotland on alcohol, we brought in minimum unit pricing; on smoking, we brought in the end of smoking in public places. This is a medical intervention that we wish to pursue in order to save people’s lives. Glasgow, where it can, has applied for a heroin-assisted treatment programme; when that is up and running, it will be able to treat 60 people, but there are an estimated 400 to 500 people who inject publicly within Glasgow city centre alone. That medical heroin-assisted treatment programme is limited in size, scope and scale, because it is a treatment programme and people must be able to engage with that.

No doubt the programme will make a huge difference to those lives, but it almost goes without saying that if 394 people died in Glasgow last year, and it can only deal with 60 people at a time, it is not enough. It is clear that we need the entry level that drug consumption rooms will give, meaning that people can go in without any kind of barrier or stigma associated with seeking help, and are able to reach those treatment services. It needs to be an easy way for people to get in and get treatment within those services.

The Scottish Government are pursuing this. We are doing what we can. We have a new drugs taskforce, chaired by Professor Catriona Matheson from the University of Stirling, which is looking at all the things we do in the Scottish Government in the round and where improvements need to be made. Both I and the Scottish Government accept that improvements need to be made, but the UK Government also need to play their part.

I will mention organisations such as Turning Point Scotland in my constituency. They drive a van around as a needle exchange, but they know that as soon as they give that needle to somebody, that person is going around to the car park at the back, to inject in a dirty back lane. That is not good enough. Not one UK Government Minister has yet come to visit Glasgow to justify their position; I urge this Minister and any of her colleagues, whoever they may be, whenever the new Prime Minister eventually turns up, to come to Glasgow and tell me why this cannot be done.

--- Later in debate ---

[The Parliamentary Under-Secretary of State for Health and Social Care (Seema Kennedy)]

It is a pleasure to serve under your chairmanship, Mr Hollobone. I begin by sending my sympathies and those of the whole House to Chelsea’s family and friends. It is a reminder to us all of the seriousness of the subject we are discussing today. I also thank the hon. Member for Manchester, Withington (Jeff Smith) for securing this important debate.

Many of the hon. Members who have spoken are devoting their parliamentary lives to this issue, because they feel so strongly about it. They have raised questions that are a matter not only for me and my Department but for other ministerial colleagues, particularly those in the Home Office, and I will transmit the many challenges that have been set for me today to those colleagues.

We have made some progress in reducing drug dependency-related harms, but, as the hon. Gentleman pointed out, this is an ancient problem. We have made progress but we are not at all complacent, and events such as the death of a girl such as Chelsea remind us that there is much more to do. I have to work with other Government Departments, public health experts and local government to continue supporting people through recovery and to prevent them from ever taking up drugs in the first place.

We published a drugs strategy in July 2017 and it is being rolled out. We know about the serious health harms of drug use, including blood-borne viruses, overdose and death, which have been outlined in great detail by hon. Members. We know that the majority of people who need treatment for drug problems are also experiencing mental health issues. We know that drugs cost £10.7 billion a year in policing, healthcare and crime costs; it is estimated that drug-fuelled theft alone costs us £6 billion a year. There is both an economic case and a moral case for us all to act on this.

It is encouraging that drug use in England and Wales is lower now than it was a decade ago. In 2016-17, 8.5% of adults had used a drug in the past year, compared with 10.1% of adults in 2006-07. More adults are successfully leaving treatment than in 2009-10, and the average waiting time to access treatment is two days.

I will pick up on some of the points that hon. Members have made. On the drug-related death figures for Scotland, health is a devolved matter, but of course—[Interruption.] I am afraid I cannot hear what the hon. Member for Glasgow Central (Alison Thewliss) is saying.

[Alison Thewliss]

The Misuse of Drugs Act is not devolved.

[Seema Kennedy]

I will come on to that. However, health is a devolved matter. Any death is a tragedy, but the figures are really worrying. I understand that the Scottish Government have appointed Professor Catriona Matheson to head up a drug deaths taskforce, to look at the main causes of death and to examine how to save lives.

My hon. Friend the Member for Central Suffolk and North Ipswich (Dr Poulter) raised the question where responsibility for public health should sit. Clearly, he thinks its sitting with local authorities is not right, but that is a broader question of public health commissioning that I do not know if we can get into here. However, he has a wealth of experience in this, and I will take away some of the points that he raised.

--- Later in debate ---

[Seema Kennedy]

I thank my right hon. Friend for that intervention.

[Alison Thewliss]

Will the Minister give way?

[Seema Kennedy]

Briefly, and then I must continue, because I want the hon. Member for Manchester, Withington to be able to make his concluding remarks.

[Alison Thewliss]

The Minister talks about there being no legal framework, but it is the job of the UK Government to provide that. If she wants any assistance, I have a 10-minute rule Bill still waiting to be heard that she could implement.

[Seema Kennedy]

As I say, that is a matter for the Home Office. I sense the hon. Lady’s frustration, but I am not responsible for that area. I have already said twice that I am happy to take that point away. Tabling business in the Chamber really is not my responsibility. I sense and am cognisant of the frustration in the House.

Under the 2017 drug strategy, we are involved in delivering actions across four themes: reducing demand to prevent drug use and its escalation; restricting supply; building recovery; and a new strand focused on global action, which is important. We need a partnership-based approach alongside the treatment system; other partners, such as the mental health and criminal justice systems, have key roles to play in securing the drug strategy’s aims.

I attend a cross-ministerial drug strategy board with Ministers from the Ministry of Housing, Communities and Local Government, the Home Office, the Ministry of Justice and representatives of Public Health England. Additionally, the Home Secretary has appointed Professor Dame Carol Black to lead a major review of drugs, looking at a range of issues, including the system of support and enforcement around drug misuse, to inform our thinking about tackling drug harms. Dame Carol will report later this summer.

I acknowledge the concerns about the funding of public health services, and that local authorities need to make difficult choices about how they spend their money to be able to continue providing effective drug treatment services. Local authorities will receive £3.1 billion in this financial year, ring-fenced exclusively for use on public health, including drug addiction. In addition, we are investing more than £16 billion for public health over the five years to the end of 2020. It is a condition of the public health grant that local authorities have regard to the need to improve the take-up and outcomes from drug and alcohol misuse treatment services. Public health funding is a matter for the next spending review, in which it will be looked at in the light of the best available evidence.